Chapter 5

Normalized Value

At $12.95, Vital Farms trades at about 9x its record fiscal-2025 earnings and 4.6x that year's adjusted EBITDA — multiples that look cheap only because fiscal 2025 was the peak of the cycle. Management guides 2026 EBITDA to near zero and a recovery to double-digit margins in 2027. The valuation is most sensitive to the normalized operating margin; on the same ~$800 million of revenue, plausible margin assumptions produce earnings anywhere from $0.18 to $1.54 a share.

What you pay today

Fiscal 2025 was a record year: net revenue of $759.4 million, net income of $66.3 million, diluted EPS of $1.44, and adjusted EBITDA of $114.0 million — a 15.0% margin [1]. Against a $12.95 share price and about 44.6 million shares, the equity is worth roughly $577 million. Net of $51 million of cash and investment securities, enterprise value is about $526 million.

Sources: FY2025 net income, EPS and adjusted EBITDA, Q4/FY2025 earnings release [2]; cash, securities and no-debt balance sheet [3]; price and share count per market data.

The trailing figures are the source of the "cheap" impression — 9x earnings and under 5x EBITDA are low marks for a brand growing revenue at a mid-20s percentage rate. The problem is what sits inside the denominator. Fiscal 2025 earned a 15.0% adjusted EBITDA margin, the highest in the company's history and roughly triple the level of only three years earlier. For fiscal 2026, management guides adjusted EBITDA to $0–10 million on revenue of $775–800 million — a margin near 1% — as it spends an estimated $32 million to manage an oversupply of eggs and exits the butter business [4]. On that guided number, the forward EV/EBITDA multiple is not low; it is undefined. The trailing multiple prices earnings power the company itself says will disappear for a year.

The de-rating that carried the stock here reflects exactly that. At the August 2025 peak near $52, the equity was worth about $2.3 billion — roughly 20x the $114 million of adjusted EBITDA fiscal 2025 went on to report. The same EBITDA base now carries an enterprise value of about $526 million, or 4.6x. The multiple has done most of the work; the earnings base has not yet moved.

Source: derived from FY2025 adjusted EBITDA of $114.0 million [5] and peak/current market values per price data.

The margin is the valuation

Because revenue is comparatively stable — the 2026 guide of $775–800 million sits close to 2025's $759 million — the earnings the reader is buying depend almost entirely on where the operating margin settles once the 2026 supply-management costs roll off. The table below holds normalized revenue at roughly $820 million and flexes only the through-cycle adjusted EBITDA margin. Net income is built down from EBITDA using depreciation of about $18 million (rising as the new plants come on line), stock-based compensation near $14 million, modest net interest income, and a 26% tax rate.

Source: derived from reported fiscal-2025 financials and the fiscal-2026 revenue guide; normalized revenue held at ~$820M [6][7].

The spread is the point. The same revenue produces $0.18 or $1.54 of earnings — an eight-fold range — depending only on the normalized margin. At a 15% margin the stock is genuinely cheap at roughly 8x earnings; at a 5% margin it is a value trap at more than 70x. The valuation is most sensitive to this single variable, and the depreciation from Vital's newly built capacity amplifies the downside: at a low EBITDA margin, fixed plant costs consume most of what is left, so net income falls faster than the margin does.

Management's own roadmap sits between the top two rows. On the Q1 2026 call it guided gross margin back to 30% by late in the fourth quarter and "underlying adjusted EBITDA margin to get back to double-digits in 2027," describing a "clear path back to the earnings profile implied by our long-term model" [8]. The 2030 framework is more ambitious still: $2 billion of revenue at a 15–17% adjusted EBITDA margin [9]. Buying the "Recovery" row means underwriting that the double-digit target is reached and held.

What the price implies

Read the other way, $12.95 is not pricing the recovery — nor a permanent impairment. To trade at a normal packaged-foods multiple of roughly 10x EV/EBITDA, today's $526 million enterprise value implies normalized adjusted EBITDA near $53 million, or about 6–7% of $820 million of revenue. That is well above the ~1% guided for 2026 and well below the 15% earned in 2025. In plain terms, the market is paying for margins that heal part of the way out of the 2026 trough and then stall in the mid-single digits.

Consensus lines up with that reading. The sell-side mean price target is $12.00 — below the current price — with a $10–16 range. Analysts have cut fiscal-2027 EPS from $1.39 ninety days ago to $0.44 now, and the revisions are still moving down. A $0.44 estimate implies a low-single-digit net margin, closer to the "Structural reset" row than to management's double-digit guidance.

Source: consensus estimates (9–10 analysts), as of July 2026.

So the arithmetic gap that defines the opportunity is narrow but real: the price and the Street both embed a partial, mid-single-digit recovery; management underwrites a return to double digits; and the reader's return depends on which of those margins actually arrives. The upside case is not that the multiple is wrong — at 4.6x trailing EBITDA it is demonstrably low — but that the earnings base recovers faster than consensus now expects.

The case against normalization

The through-line of this report asks whether a premium egg brand can turn its lead into durable cash, or whether it stays hostage to commodity swings and private-label entry. A valuation built on "2026 is a trough" deserves the opposite hypothesis given a fair hearing: that 2026 is not a discrete shock but a structural reset of the margin, in which case the mid-single-digit outcome is the normalized one and the stock is fairly valued to expensive.

The bear mechanism is specific. The 2026 damage came from a collapse in commodity egg prices — breaker eggs near $0.10 a dozen — which widened the price gap between Vital's outdoor-access eggs and the conventional shelf, cut trial, and forced the company to dump excess supply into no-revenue channels. If cheap commodity eggs persist and private-label pasture-raised keeps undercutting — its share of the pasture-raised segment rose roughly ten-fold while Vital's roughly tripled, as detailed in Category and Moat — then the premium's pricing power is structurally capped, and the "double-digit margin in 2027" does not arrive on schedule. The newly built capacity works against the reset case too: depreciation and fixed plant cost are now permanent, so the asset-light margin profile of Vital's earlier years is unlikely to return in full.

Three facts keep the reset case alive rather than academic. Consensus itself does not believe the recovery — a $0.44 fiscal-2027 estimate and a $12.00 mean target embed only a partial heal. The estimate trend is still down, not stabilizing. And management's recovery is explicitly conditioned on prices holding: the CFO warned that if outdoor-access retail prices "erode further," Vital would spend more to close price gaps, cutting revenue and profit further [10]. The recovery is a forecast resting on an assumption the company does not control.

The bull's answer is equally concrete, and belongs in the same frame: the pasture-raised category is still growing volume at a high-20s percentage rate off roughly 10% household penetration (Category and Moat); the $32 million of 2026 supply-management cost is identified and one-time; management has real cost levers in the butter exit, a headcount reduction, and capex cut from $140–150 million to $70–75 million [11]; and the debt-free balance sheet lets the company wait out the trough without financing pressure (Cash Conversion). The evidence does not settle the question. What would settle it is measurable within four to six quarters: whether gross margin returns toward 30% by late 2026 and whether the 2027 adjusted EBITDA margin re-enters double digits.

Downside and the balance-sheet floor

The debt-free balance sheet is a genuine strength, but it should not be mistaken for a price floor near current levels. Book value is about $7.42 a share; net cash is roughly $1 a share. At $12.95 the stock trades at about 1.75x book, so the tangible-asset floor sits some 43% below the current price. The absence of debt removes solvency risk — covered in Cash Conversion — but it does not stop the multiple compressing toward book if the recovery stalls. The May 2026 low of $8.28, about 1.1x book, is a recent demonstration of how far sentiment can travel when the earnings base is in doubt.

Management's capital-allocation signal has been mixed on timing. The board authorized a $100 million, two-year buyback in February 2026, framed as buying "particularly during periods where management believes the public market price does not fully reflect intrinsic value" [12]. It then spent the first $20 million in the first quarter, repurchasing over one million shares while the stock averaged about $23.63 — nearly double today's price — leaving $80 million authorized as of late March [13]. The remaining authorization, deployable now near book value, is worth more than the tranche already spent above it.

Source: book value derived from Q1 FY2026 stockholders' equity of $330.9 million over ~44.6M shares [14]; price anchors per market data.

What would decide it

The valuation resolves on two falsifiable, near-term markers, both stated by management and checkable in the quarterly filings. First, gross margin: guided back to 30% by late in the fourth quarter of 2026 [15] against roughly 37% in 2025 and a 2026 trough — the reported gross-margin line each quarter tells you whether the price gap is closing. Second, the fiscal-2027 adjusted EBITDA margin: a return to double digits validates the "Recovery" or "Partial heal" rows and the low trailing multiple; a stall in the mid-single digits validates the reset case and makes today's price full. On the evidence available now — a low trailing multiple, a stable revenue base, a debt-free balance sheet, but a still-falling consensus and a recovery contingent on egg prices the company cannot set — the setup rewards patience only if the margin heals, and the next two to three prints will show which way it is going.